Last reviewed · How we verify

TIVA - Neostigmine 30

Pontificia Universidade Catolica de Sao Paulo · FDA-approved active Small molecule Quality 2/100

TIVA - Neostigmine 30 is a Small molecule drug developed by Pontificia Universidade Catolica de Sao Paulo. It is currently FDA-approved. Also known as: TIVA.

At a glance

Generic nameTIVA - Neostigmine 30
Also known asTIVA
SponsorPontificia Universidade Catolica de Sao Paulo
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TIVA - Neostigmine 30

What is TIVA - Neostigmine 30?

TIVA - Neostigmine 30 is a Small molecule drug developed by Pontificia Universidade Catolica de Sao Paulo.

Who makes TIVA - Neostigmine 30?

TIVA - Neostigmine 30 is developed and marketed by Pontificia Universidade Catolica de Sao Paulo (see full Pontificia Universidade Catolica de Sao Paulo pipeline at /company/pontificia-universidade-catolica-de-sao-paulo).

Is TIVA - Neostigmine 30 also known as anything else?

TIVA - Neostigmine 30 is also known as TIVA.

What development phase is TIVA - Neostigmine 30 in?

TIVA - Neostigmine 30 is FDA-approved (marketed).

Related